Gsk Share Discussion Threads

[montyhedge] 28/4/2009 07:44

madoff
Experts saying add £1.5 billion a year to revenue, a blockbuster.

[madoff with cash] 28/4/2009 07:43

wonga, that's not a completely new, revolutionary type of drug. a freind of mine, a physician, told me it halt the growth of tissue and hence indirectly halt the development of cancer. more exciting drug should come from gene therapy and nano tech sector. what current big pharmas are engaged in is still inconventional stuff. still it might genereate good revenue for gsk.

[montyhedge] 28/4/2009 07:38

Tests were good, but of course needs FDA approval. But look at this shows GSK growing very well.

[shammytime] 28/4/2009 07:29

Monty, when are you expecting the cancer news?

[shammytime] 28/4/2009 07:28

Tempted by some of these. Looking for a 30p rise today at least.

[montyhedge] 28/4/2009 07:20

Over 1100p today, thats without swine news but the prostate cancer drug, could add £1 billion to revenue.

[montyhedge] 28/4/2009 07:17

Watch the price last 45 minutes of trading this afternoon, big spike as the bears close, before ex divi tomorrow.

[wongauk] 28/4/2009 07:09

Agreed. Sorry, I misunderstood your last post. Good luck.

[montyhedge] 28/4/2009 07:08

Wonga
I'm holding for 1150p plus dividend on top of 14p, no need to sell, even without swine flu news, that prostate cancer news should put 100p on the price anyway.

[montyhedge] 28/4/2009 07:05

Bears panicking if they don't close today, another 14p they will have to pay back, ex div tomorrow. Slaughter of the bears later this afternoon.

[wongauk] 28/4/2009 07:05

monty - will you hold for tommorrow or sell today?

[montyhedge] 28/4/2009 07:01

Without the flu news, this should be 1150p with the prostate cancer new drug.

[wongauk] 28/4/2009 07:00

1075p Open

[montyhedge] 28/4/2009 07:00

Ex Dividend tomorrow another 14p add on your profit, normally share fall by the ex div amount, but this won't. 1150p with dividend.

[james dean] 28/4/2009 06:57

From Sharecast this morning:

The world's first prevention for prostate cancer could be on the market in about a year after a key trial of GlaxoSmithKline's Avodart treatment was found to reduce the chance of at-risk patients developing the disease by nearly a quarter. GSK unveiled the results of its four-year, 8,000-patient phase III trial of Avodart at the American Urological Association meeting in Chicago, reports the Times.

Regards.

DYOR

[wongauk] 28/4/2009 06:55

Ok, thanks for the update Spondon lol :-)

[sat69] 28/4/2009 06:54

FTSE futures down 62pts

[spondon] 28/4/2009 06:47

Lycopene in tomatoes and pelvic floor exercise also meant to be mildly preventative

[wongauk] 28/4/2009 06:14

madoff - Prostate cancer is the second biggest killer in men! This is the worlds first preventative medication..... what can you not find exciting about that? Would you take it?..... just interested :-)

[madoff with cash] 28/4/2009 03:31

there's another one.

Cipla Can Supply Generic Tamiflu Article

By RUMMAN AHMED and SHIKHAR BALWANI
BANGALORE -- Indian drug maker Cipla Ltd. said Monday it can supply 1.5 million doses of a Tamiflu copycat in four-six weeks' time in response to a possible global demand for the anti-viral medication following an outbreak of swine flu.

"We have stocks in readiness," Amar Lulla, Cipla's chief executive and joint managing director, told Dow Jones Newswires.

Cipla is one of the big Indian drug companies that makes a generic version of Roche Holding AG's Tamiflu. Tests have shown the drug is effective against swine flu, which occurs in pigs and is passed to humans in rare cases.

Reports said at least 103 people have died in Mexico from the flu. The World Health Organization has declared the flu to be a "public health emergency of international concern" and governments are taking precautions to screen for the virus.

Cipla will look to export Tamiflu if there is a need, Lulla said, adding, the company is yet to hear from the Indian government on stockpiling the drug.

Cipla shares jumped almost 7% on expectations the company will benefit from higher sales of Tamiflu and on reporting a better-than-expected quarterly profit Friday.

IIFL Capital's pharma analyst Bino Pathiparampil, however, said Indian generic drug makers were likely to see limited immediate gains from Tamiflu sales. "I think Roche and GSK have sufficient stocks of their patented anti-flu drugs given the current extent of the illness."

GlaxoSmithKline PLC sells an anti-flu drug, Relenza.

"If it (the outbreak) prolongs, and these stocks are insufficient, Indian pharmas may see some demand," Mr. Pathiparampil added.

Cipla sells its version of Tamiflu to government-run hospitals in India. Its drug is priced at 1,000 rupees ($20.1) for a course of 10 capsules.

"The authorities should stockpile (the drug). You never know when you'll need it," Mr. Lulla said.

He declined to comment on the potential sales the company expects from supplies of its version of Tamiflu.

Write to Dow Jones Newswires editors at [e-mail]

[madoff with cash] 27/4/2009 23:55

from wsj. to be honest, i don't find particularly exciting about the new drug. but the market might react differently.


CHICAGO -- GlaxoSmithKline PLC's drug Avodart lowered risk of prostate cancer by 23% in men with elevated risk of the disease, a new study found.

Avodart, known generically as dutasteride, is already on the market for treatment of enlarged prostates--a condition known as benign prostatic hyperplasa, or BPH.

In a study involving 8,231 patients with increased risk of prostate cancer, 22.5% of men taking Avodart were diagnosed with prostate cancer after four years compared to 29% who were taking a placebo. All told, 659 men who were taking the drug developed prostate cancer during the course of the study compared with 857 who took a dummy pill.

The men were determined to be at high risk based on elevated levels of a risk marker called prostate-specific antigen, or PSA. Biopsies taken of prostate tissue before they entered the trial didn't detect cancer.

"We think this is very good news," said Gerald L. Andriole, chief of urologic surgery at Washington University in St. Louis, who led the study. He is presenting the data Monday at a meeting of the American Urological Association in Chicago.

There aren't any drugs currently approved to reduce risk of the disease in men with heightened prostate cancer risk.

Dr. Andriole said Avodart, which shrinks tissue in enlarged prostates by 20%, may work against cancer by reducing the size of tumors or slowing their growth.

[madoff with cash] 27/4/2009 22:50

monty, i'm all over china. currently i'm in the south west province called yunnan. shanghai is perhaps the most westernised city in china. pollution is horrible. unless you speak chinese, it will drive you crazy. me back to uk for a while next month. and be back in china soon again. lots of opportunity. but must speak chinese which i'll take a crash course in london and somewhre in china.

[lionheart79] 27/4/2009 22:23

hehe Sat - you forgot to mention that 'he who shall not be named' uses long term fundamental arguments to back up his short term momentum trades ;)